Shore Capital Reaffirms “House Stock” Rating for Oxford BioDynamics (LON:OBD)

Oxford BioDynamics (LON:OBD)‘s stock had its “house stock” rating restated by Shore Capital in a report released on Thursday,Digital Look reports.

Oxford BioDynamics Trading Down 4.6 %

LON:OBD opened at GBX 0.50 ($0.01) on Thursday. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The firm has a 50-day moving average of GBX 0.60 and a 200-day moving average of GBX 1.76. The company has a market cap of £9.45 million, a PE ratio of -0.09 and a beta of 0.42. Oxford BioDynamics has a one year low of GBX 0.45 ($0.01) and a one year high of GBX 10.60 ($0.14).

Oxford BioDynamics (LON:OBD) last posted its earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) EPS for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.